pp-268 Solution for injection/infusion
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Neurodegenerative diseases (Alzheimer's disease and other neurological disorders)
Clinical stage: Phase 3
Modality: Peptide (GLP-1 receptor agonist)
Mechanism & Target: GLP-1 receptor agonist
Route & form: SC injection
Differentiation: A proprietary approach that addresses the treatment of Alzheimer's Disease (AD) and other neurological disorders through a mechanism of action differentiated from current therapies.
Manufacturer #39680
A late-stage clinical biopharmaceutical company focused on unmet medical needs. Developing a biologic therapeutic targeting unmet medical needs with global development focus. Pipeline positioned for regulatory advancement in key markets.
None